Gut Health Protocol
BPC-157 + KPV + Larazotide
Restore gut barrier integrity, reduce intestinal inflammation, and repair mucosal damage
Overview
A targeted gut health combination addressing three distinct aspects of intestinal dysfunction: mucosal repair (BPC-157), mucosal inflammation (KPV), and intestinal permeability or "leaky gut" (Larazotide). This protocol is designed for individuals with chronic gut issues including IBD, IBS, or post-antibiotic gut damage.
Component Peptides
Mucosal healing — promotes GI tissue repair, protects against NSAID damage, modulates nitric oxide system
Anti-inflammatory tripeptide — fragment of alpha-MSH that reduces mucosal inflammation via NF-kB inhibition
Tight junction modulator — reduces intestinal permeability by regulating zonulin pathways
Expected Timeline
Symptom relief (bloating, discomfort) within 1-2 weeks. Noticeable improvement in digestive function at 4-6 weeks. Significant gut barrier restoration by 8-12 weeks.
Safety Notes
- BPC-157 oral bioavailability is debated — subcutaneous may be more reliable
- KPV is generally well-tolerated with minimal reported side effects
- Larazotide has a good safety profile from clinical trials
- Start with lower doses and titrate up over 1-2 weeks
- Monitor for changes in bowel habits during initial phase
Bloodwork Recommendations
- Comprehensive metabolic panel
- CRP and calprotectin (inflammation markers)
- Celiac panel if not previously tested
- Zonulin levels (intestinal permeability marker)
- Food sensitivity panel (consider IgG/IgA testing)
Contraindications
- Active cancer, particularly GI cancers
- Pregnancy or breastfeeding
- Concurrent immunosuppressive therapy (consult physician)
- Known hypersensitivity to any component
Evidence Assessment
Individual peptides have varying levels of evidence. BPC-157 has extensive animal data for GI healing. KPV has preclinical data showing anti-inflammatory effects in colitis models. Larazotide has completed Phase III clinical trials for celiac disease and is the most clinically advanced of the three. The combination is theoretical but mechanistically complementary.
References
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612-1632.
- Kannengiesser K, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflamm Bowel Dis. 2008;14(3):324-331.
- Leffler DA, et al. "Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet." Gastroenterology. 2015;148(7):1311-1319.
Research Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All products referenced are for in vitro laboratory research use only. Consult a qualified healthcare professional before beginning any research protocol.